MAZE
Maze Therapeutics, Inc.$24.36-0.30 (-1.24%)Prev Close$24.67·MCap$1.45B·P/E—·Vol299.0K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
35
$16.16M
◆
Net Activity
Net Seller
$16.16M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Maze Therapeutics, Inc. (MAZE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 35 insider sales totaling $16.16M. The most recent insider transaction was by Bernstein Harold (officer: President, R&D & CMO), who sold $254.5K worth of shares on Sep 8, 2026. Maze Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.45B.
MAZE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 9,705 | $26.22 | $254.5K | 0Exit |
| Sep 4, 2026 | Dandekar Atul | officer: CSBO | Sell | 6,434 | $26.24 | $168.8K | 35,950 |
| Sep 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 10,295 | $26.24 | $270.1K | 15,519-40% |
| Sep 4, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 22,638 | $26.24 | $594.0K | 40,148-36% |
| Sep 4, 2026 | Courtney Phillips | officer: GC and Corp. Secretary | Sell | 3,993 | $26.24 | $104.8K | 9,262-30% |
| Sep 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.29 | $907.0K | 223,355 |
| Sep 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,141 | $26.36 | $425.5K | 0Exit |
| Aug 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.58 | $206.8K | 26,250 |
| Aug 14, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,142 | $27.61 | $445.6K | 0Exit |
| Aug 5, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.73 | $922.3K | 256,867 |
| Jul 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.34 | $205.0K | 26,650 |
| Jul 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,609 | $29.90 | $436.9K | 1,200-92% |
| Jul 2, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $29.98 | $1.03M | 288,768 |
| Jul 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $28.02 | $210.2K | 26,250 |
| Jun 24, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 27,858 | $26.04 | $725.5K | 342,944 |
| Jun 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,853 | $25.66 | $381.1K | 1,600-90% |
| Jun 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 6,643 | $26.20 | $174.0K | 344,897 |
| Jun 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $26.34 | $197.6K | 24,808 |
| May 27, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 32,564 | $26.01 | $847.0K | 376,569 |
| May 18, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $26.22 | $393.4K | 0Exit |
| May 18, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 1,938 | $26.00 | $50.4K | 381,073 |
| May 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $25.37 | $190.3K | 10,503-42% |
| Apr 2, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 2,500 | $29.44 | $73.6K | 13,265 |
| Apr 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $29.46 | $441.9K | 3,648-80% |
| Apr 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $29.34 | $220.0K | 11,293-40% |
| Mar 20, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $49.10 | $736.4K | 8,839-63% |
| Mar 12, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 30,000 | $50.45 | $1.51M | 348-99% |
| Feb 4, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $46.04 | $230.2K | 17,765 |
| Feb 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $46.02 | $690.3K | 14,400-51% |
| Feb 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $44.27 | $332.0K | 16,803-31% |
| Jan 26, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $45.52 | $227.6K | 12,965-28% |
| Jan 9, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 25,156 | $40.20 | $1.01M | 0Exit |
| Jan 8, 2026 | Sohn Catherine A. | director | Sell | 29,413 | $39.07 | $1.15M | 0Exit |
| Jan 6, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $39.15 | $195.8K | 15,560 |
| Jan 6, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 4,844 | $40.39 | $195.7K | 0Exit |
| Sep 15, 2025 | SCHELLER RICHARD H | Director | Sell | 20,744 | $22.37 | $464.0K | 0 |
MAZE Insider Buying Activity
The following table shows recent insider purchases of Maze Therapeutics, Inc. (MAZE) stock reported via SEC Form 4 filings.
No insider buying activity found for MAZE in the last 12 months.
MAZE Insider Selling Activity
The following table shows recent insider sales of Maze Therapeutics, Inc. (MAZE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 9,705 | $26.22 | $254.5K | 0Exit |
| Sep 4, 2026 | Dandekar Atul | officer: CSBO | Sell | 6,434 | $26.24 | $168.8K | 35,950 |
| Sep 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 10,295 | $26.24 | $270.1K | 15,519-40% |
| Sep 4, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 22,638 | $26.24 | $594.0K | 40,148-36% |
| Sep 4, 2026 | Courtney Phillips | officer: GC and Corp. Secretary | Sell | 3,993 | $26.24 | $104.8K | 9,262-30% |
| Sep 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.29 | $907.0K | 223,355 |
| Sep 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,141 | $26.36 | $425.5K | 0Exit |
| Aug 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.58 | $206.8K | 26,250 |
| Aug 14, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 16,142 | $27.61 | $445.6K | 0Exit |
| Aug 5, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $26.73 | $922.3K | 256,867 |
| Jul 31, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $27.34 | $205.0K | 26,650 |
| Jul 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,609 | $29.90 | $436.9K | 1,200-92% |
| Jul 2, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 34,501 | $29.98 | $1.03M | 288,768 |
| Jul 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $28.02 | $210.2K | 26,250 |
| Jun 24, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 27,858 | $26.04 | $725.5K | 342,944 |
| Jun 3, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 14,853 | $25.66 | $381.1K | 1,600-90% |
| Jun 3, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 6,643 | $26.20 | $174.0K | 344,897 |
| Jun 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $26.34 | $197.6K | 24,808 |
| May 27, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 32,564 | $26.01 | $847.0K | 376,569 |
| May 18, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $26.22 | $393.4K | 0Exit |
| May 18, 2026 | Coloma Jason V | director, officer: Chief Executive Officer | Sell | 1,938 | $26.00 | $50.4K | 381,073 |
| May 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $25.37 | $190.3K | 10,503-42% |
| Apr 2, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 2,500 | $29.44 | $73.6K | 13,265 |
| Apr 2, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $29.46 | $441.9K | 3,648-80% |
| Apr 1, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $29.34 | $220.0K | 11,293-40% |
| Mar 20, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $49.10 | $736.4K | 8,839-63% |
| Mar 12, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 30,000 | $50.45 | $1.51M | 348-99% |
| Feb 4, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $46.04 | $230.2K | 17,765 |
| Feb 4, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 15,000 | $46.02 | $690.3K | 14,400-51% |
| Feb 2, 2026 | Dandekar Atul | officer: CSBO | Sell | 7,500 | $44.27 | $332.0K | 16,803-31% |
| Jan 26, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $45.52 | $227.6K | 12,965-28% |
| Jan 9, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 25,156 | $40.20 | $1.01M | 0Exit |
| Jan 8, 2026 | Sohn Catherine A. | director | Sell | 29,413 | $39.07 | $1.15M | 0Exit |
| Jan 6, 2026 | Bachrodt Amy | officer: SVP, Finance | Sell | 5,000 | $39.15 | $195.8K | 15,560 |
| Jan 6, 2026 | Bernstein Harold | officer: President, R&D & CMO | Sell | 4,844 | $40.39 | $195.7K | 0Exit |
| Sep 15, 2025 | SCHELLER RICHARD H | Director | Sell | 20,744 | $22.37 | $464.0K | 0 |
MAZE Insiders
Similar Stocks to MAZE
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B